ONCOFID-P-B (Paclitaxel-Hyaluronic Acid) In The Intravesical Therapy Of Patients With Non-Muscle Invasive Cancer Of The Bladder. A Phase II Marker Lesion Study.

Trial Profile

ONCOFID-P-B (Paclitaxel-Hyaluronic Acid) In The Intravesical Therapy Of Patients With Non-Muscle Invasive Cancer Of The Bladder. A Phase II Marker Lesion Study.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Paclitaxel-hyaluronic acid conjugate (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Fidia Farmaceutici
  • Most Recent Events

    • 22 Oct 2016 This trial has been completed in Germany (end date: 4 Oct 2016).
    • 11 Oct 2016 This trial was completed inn Spain (end date: 2016-10-04), according to European Clinical Trials Database.
    • 15 Sep 2012 Planned end date changed from 17 Sep 2012 to 17 Sep 2013 as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top